[
  {
    "title": "首药控股(688197.SH)：选择性RET抑制剂SY-5007开展关键性临床试验",
    "href": "http://stock.jrj.com.cn/2023/01/04155437258420.shtml",
    "datetime": "2023-01-04 15:54:17",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)第三季度净亏损3508.48万元",
    "href": "http://stock.jrj.com.cn/2022/10/30154737097179.shtml",
    "datetime": "2022-10-30 15:47:33",
    "code": "688197"
  },
  {
    "title": "首药控股(688197)首次公开发行网下配售限售股于2022年9月23日上市流通",
    "href": "http://stock.jrj.com.cn/2022/09/15090936996041.shtml",
    "datetime": "2022-09-15 09:09:22",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)：187.9万股限售股将于9月23日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/09/14180136994744.shtml",
    "datetime": "2022-09-14 18:01:01",
    "code": "688197"
  },
  {
    "title": "首药控股披露2022年半年报 实现营收178.52万元",
    "href": "http://stock.jrj.com.cn/2022/08/16110736903477.shtml",
    "datetime": "2022-08-16 11:07:19",
    "code": "688197"
  },
  {
    "title": "首药控股半年报：持续加码研发 核心产品稳步快速推进中",
    "href": "http://stock.jrj.com.cn/2022/08/16104536903402.shtml",
    "datetime": "2022-08-16 10:45:13",
    "code": "688197"
  },
  {
    "title": "首药控股2022年上半年亏损8407.53万 同比亏损增加 研发产品尚未实现销售收入",
    "href": "http://stock.jrj.com.cn/2022/08/15223236902121.shtml",
    "datetime": "2022-08-15 22:32:54",
    "code": "688197"
  },
  {
    "title": "首药控股(688197)：2022年度日常关联交易预计",
    "href": "http://stock.jrj.com.cn/2022/08/15175336901008.shtml",
    "datetime": "2022-08-15 17:53:10",
    "code": "688197"
  },
  {
    "title": "首药控股业绩说明会：持续研发提升核心竞争力 首个产品2023年底或实现初步商业化",
    "href": "http://stock.jrj.com.cn/2022/05/13163936646758.shtml",
    "datetime": "2022-05-13 16:39:27",
    "code": "688197"
  },
  {
    "title": "首药控股（688197）：于2022年5月10日15:00开始、地点等举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/05/12084136640337.shtml",
    "datetime": "2022-05-12 08:41:56",
    "code": "688197"
  },
  {
    "title": "首药控股2022年第一季度亏损5066.23万同比亏损增加 药品合作开发收入未到结算期",
    "href": "http://stock.jrj.com.cn/2022/05/04113236554334.shtml",
    "datetime": "2022-05-04 11:32:57",
    "code": "688197"
  },
  {
    "title": "首药控股回应“一季度营收708元”质疑：目前尚无获批上市销售的药品",
    "href": "http://stock.jrj.com.cn/2022/04/29084736500389.shtml",
    "datetime": "2022-04-29 08:47:30",
    "code": "688197"
  },
  {
    "title": "首药控股2021年亏损1.45亿同比亏损减少 总经理李文军薪酬57.20万",
    "href": "http://stock.jrj.com.cn/2022/04/28113136491299.shtml",
    "datetime": "2022-04-28 11:31:40",
    "code": "688197"
  },
  {
    "title": "首药控股：发布2021年年报 持续创新蓄力突破",
    "href": "http://stock.jrj.com.cn/2022/04/27094736481474.shtml",
    "datetime": "2022-04-27 09:47:34",
    "code": "688197"
  },
  {
    "title": "首药控股披露2021年年报 实现营收1303.25万元",
    "href": "http://stock.jrj.com.cn/2022/04/27091736481304.shtml",
    "datetime": "2022-04-27 09:17:17",
    "code": "688197"
  },
  {
    "title": "首药控股(688197)：高级管理人员辞职",
    "href": "http://stock.jrj.com.cn/2022/04/27085636481068.shtml",
    "datetime": "2022-04-27 08:56:06",
    "code": "688197"
  },
  {
    "title": "首药控股：三代ALK抑制剂SY-3505临床I期研究结果亮相欧洲肺癌大会",
    "href": "http://stock.jrj.com.cn/2022/04/10170236321774.shtml",
    "datetime": "2022-04-10 17:02:02",
    "code": "688197"
  },
  {
    "title": "首药控股李文军：创新需要有眼光和敢闯精神 做有责任心的创新药企业",
    "href": "http://stock.jrj.com.cn/2022/04/08205936321775.shtml",
    "datetime": "2022-04-08 20:59:28",
    "code": "688197"
  },
  {
    "title": "首药控股李文军：创新需要有眼光和敢闯精神 做有责任心的创新药企业",
    "href": "http://stock.jrj.com.cn/2022/04/08205936274288.shtml",
    "datetime": "2022-04-08 20:59:28",
    "code": "688197"
  },
  {
    "title": "科创板新股首药控股、创业板新股和顺科技上市竞价破发",
    "href": "http://stock.jrj.com.cn/2022/03/23092934863983.shtml",
    "datetime": "2022-03-23 09:29:51",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)：将于3月23日在上交所上市",
    "href": "http://stock.jrj.com.cn/2022/03/21202134857378.shtml",
    "datetime": "2022-03-21 20:21:47",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)：中信建投投资获配148.72万股、网上摇号中签号共21267个",
    "href": "http://stock.jrj.com.cn/2022/03/15192234830453.shtml",
    "datetime": "2022-03-15 19:22:00",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)：网上发行最终中签率为0.036%",
    "href": "http://stock.jrj.com.cn/2022/03/14190934825342.shtml",
    "datetime": "2022-03-14 19:09:06",
    "code": "688197"
  },
  {
    "title": "首药控股(688197.SH)IPO定价为39.90元/股 3月14日申购",
    "href": "http://stock.jrj.com.cn/2022/03/10190634810440.shtml",
    "datetime": "2022-03-10 19:06:59",
    "code": "688197"
  },
  {
    "title": "科创板IPO新动态！首药控股回复注册环节反馈意见落实函",
    "href": "http://stock.jrj.com.cn/2022/02/10090934316945.shtml",
    "datetime": "2022-02-10 09:09:29",
    "code": "688197"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股公司首药控股于科创板IPO获证监会同意注册",
    "href": "http://stock.jrj.com.cn/2022/02/09160034313430.shtml",
    "datetime": "2022-02-09 16:00:50",
    "code": "688197"
  },
  {
    "title": "首药控股过会：今年IPO过关第244家 中信建投过18.5单",
    "href": "http://stock.jrj.com.cn/2021/08/04094633199843.shtml",
    "datetime": "2021-08-04 09:46:00",
    "code": "688197"
  },
  {
    "title": "相关产品上市风险是否大大增加？首药控股科创板IPO成功过会",
    "href": "http://stock.jrj.com.cn/2021/08/04091733199641.shtml",
    "datetime": "2021-08-04 09:17:17",
    "code": "688197"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股的首药控股于科创板IPO通过上市委审议",
    "href": "http://stock.jrj.com.cn/2021/08/03193633197320.shtml",
    "datetime": "2021-08-03 19:36:00",
    "code": "688197"
  },
  {
    "title": "首药控股IPO：产品全部在研 投资者以Pre-IPO估值承受天使投资的风险",
    "href": "http://stock.jrj.com.cn/2021/08/03182033197005.shtml",
    "datetime": "2021-08-03 18:20:18",
    "code": "688197"
  },
  {
    "title": "三年亏损约四亿元 首药控股8月3日科创板上会接受审核",
    "href": "http://stock.jrj.com.cn/2021/07/28134933163552.shtml",
    "datetime": "2021-07-28 13:49:34",
    "code": "688197"
  },
  {
    "title": "首药控股8月3日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2021/07/27194333159488.shtml",
    "datetime": "2021-07-27 19:43:00",
    "code": "688197"
  },
  {
    "title": "进展！首药控股冲刺科创板IPO回复首轮24问",
    "href": "http://stock.jrj.com.cn/2021/06/01091332854822.shtml",
    "datetime": "2021-06-01 09:13:52",
    "code": "688197"
  },
  {
    "title": "双鹭药业：2020年报里提到的3家参股公司年内IPO系指首药控股、长风药业和星昊医药",
    "href": "http://stock.jrj.com.cn/2021/05/10173432730485.shtml",
    "datetime": "2021-05-10 17:34:39",
    "code": "688197"
  },
  {
    "title": "双鹭药业：公司投资首药控股系看好其未来发展潜力",
    "href": "http://stock.jrj.com.cn/2021/04/30191232488787.shtml",
    "datetime": "2021-04-30 19:12:46",
    "code": "688197"
  },
  {
    "title": "新进展！首药控股科创板IPO进入“已问询”状态",
    "href": "http://stock.jrj.com.cn/2021/04/14090632369206.shtml",
    "datetime": "2021-04-14 09:06:31",
    "code": "688197"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股公司首药控股科创板IPO申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2021/03/17115032150298.shtml",
    "datetime": "2021-03-17 11:50:18",
    "code": "688197"
  },
  {
    "title": "研发费用较高、业绩亏损 首药控股科创板IPO商业化待解",
    "href": "http://stock.jrj.com.cn/2021/03/17100132149729.shtml",
    "datetime": "2021-03-17 10:01:43",
    "code": "688197"
  },
  {
    "title": "首药控股拟科创板IPO，主营肿瘤和糖尿病一类新药研发和生产",
    "href": "http://stock.jrj.com.cn/2021/01/06155231646122.shtml",
    "datetime": "2021-01-06 15:52:47",
    "code": "688197"
  },
  {
    "title": "首药控股启动上市辅导：发明专利有120项",
    "href": "http://stock.jrj.com.cn/2020/12/06151531418322.shtml",
    "datetime": "2020-12-06 15:15:17",
    "code": "688197"
  }
]